NCT01294566View on ClinicalTrials.gov

FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 29, 2010

Primary Completion Date

March 23, 2011

Study Completion Date

March 23, 2011

Conditions
Gastroparesis
Interventions
DRUG

GSK1322888

1 mg, 5 mg or 25 mg capsule

DRUG

Placebo

matching placebo capsules

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01294566 - FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers | Biotech Hunter | Biotech Hunter